“Expanding AI Technology in Human Oncology: The Mission of ImpriMed, a Revolutionary Dog Cancer Treatment”
ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify the most suitable drugs for individual canine and feline blood cancers.
The startup, which centers on improving treatment outcomes of dogs and cats with cancer first, now aims to expand its precision medicine technology for human oncology applications.
“Also, the proven know-how acquired from developing AI algorithms in veterinary oncology streamlines the building of new predictive models in human oncology.
For human precision oncology, its AI software for multiple myeloma, a rare blood cancer, is in the process of approval, aiming to commercialize in 2025, Lim told TechCrunch.
ImpriMed’s unique strength is “the ability to develop and incorporate AI models into the personalized medicine service workflow,” according to Lim.
